Calorie restriction and resveratrol do not activate SIRT1 in healthy humans: a randomized controlled trial
Timmers S, de Ligt M, Phielix E, van de Weijer T, Hansen J, Moonen-Kornips E, Schaart G, Hesselink MK, Schrauwen P
Published in Diabetes Care
Methodology
Randomized double-blind placebo-controlled trial of resveratrol 150 mg/day in obese men with type 2 diabetes assessing mitochondrial and sirtuin-linked metabolic function.
Key Findings
Resveratrol failed to improve insulin sensitivity, mitochondrial function or hepatic lipid content compared with placebo.
Conclusions
Well-designed trial finds no sirtuin-mediated metabolic benefit.
Limitations
Single population; modest dose.
Supplements Studied
Resveratrol failed to improve insulin sensitivity, mitochondrial function or hepatic lipid content compared with placebo
Outcomes Measured
Resveratrol failed to improve insulin sensitivity, mitochondrial function or hepatic lipid content compared with placebo
Resveratrol failed to improve insulin sensitivity, mitochondrial function or hepatic lipid content compared with placebo
Resveratrol failed to improve insulin sensitivity, mitochondrial function or hepatic lipid content compared with placebo.
Resveratrol failed to improve insulin sensitivity, mitochondrial function or hepatic lipid content compared with placebo.
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.